The inhibition of the nicotine-activated AKT isoforms pathway may aid in the development of innovative therapeutic techniques for the prevention and treatment of metastatic tumors from smoking-caused lung cancer, which may improve the survival outcome of the patients. Here, AKT1 is linked to lung cancer.